WO2004100923A1 - Composition a usage externe administree par voie percutanee - Google Patents
Composition a usage externe administree par voie percutanee Download PDFInfo
- Publication number
- WO2004100923A1 WO2004100923A1 PCT/CN2003/000358 CN0300358W WO2004100923A1 WO 2004100923 A1 WO2004100923 A1 WO 2004100923A1 CN 0300358 W CN0300358 W CN 0300358W WO 2004100923 A1 WO2004100923 A1 WO 2004100923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- composition
- skin
- acne
- carotene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Definitions
- the present invention relates to a topical composition for transdermal administration, which can maintain and improve the skin. . technical background
- the human skin structure includes the epidermis, dermis, subcutaneous adipose tissue, sebaceous glands, sweat glands, hair, and finger cuffs.
- the thick layer under the epidermis is called the dermis, and the hair is surrounded by the surrounding hair crusts, and sebaceous glands are attached to the sides.
- the sebaceous glands can secrete sebum.
- the sebum penetrates the surface of the skin through the hair and hair loops, and then becomes a thin film of fat, which attaches to the surface of the skin and protects the skin.
- the amount of sebaceous glands affects the type of skin, and is usually divided into oily skin, dry skin and mixed skin.
- Acne is generally considered to be acne, adolescent gangrene, a chronic inflammation of the hairy pimples, the sebaceous glands.
- Acne usually appears on the forehead, around the nose, around the cheeks, and even on the back, chest, thighs, and other hairy places. It can be divided into acne type, inflammation type, and cyst type according to the symptoms.
- puberty when the gonads begin to mature, the testicles, ovaries, and adrenal glands increase in male hormones, which stimulates the sebaceous glands of the human skin, enlarges them, secretes a large amount of sebum, accumulates in the sebaceous glands and hair follicles, and becomes inflamed by bacteria.
- Blackheads or whiteheads usually form first. Acne is then infected with bacteria to form pimples, pustules, nodules, and bloating, which are acne. When male hormones are secreted too much, red, itchy, hot, hot, and peeling skin may appear on the T-shaped part of the face and the skin under the eyelids, and sometimes microvessels may even appear obviously, which is called apolipic dermatitis.
- sodium chloride can be the main body to maintain the osmotic pressure of body fluids, especially 0.9% solution is called physiological saline, but high-concentration sodium chloride solution cannot be absorbed from the skin, but stimulates the skin mucosa and causes dehydration;
- external preparations can stimulate the skin or sterilize, it is difficult to produce a moisturizing effect that prevents skin moisture from evaporating.
- glucose can increase the quality of sugar and increase the function of whole body cells, it is a nutrient that enhances the metabolic function of organisms. It also has a detoxifying effect. Even if glucose is added to a topical preparation, it is difficult to achieve the above-mentioned special effects exhibited by glucose.
- Various therapeutic agents and cosmetic agents have been used to treat various skin symptoms, for example, hydrocortisone for itching and erythema in atopic dermatitis, sulconazole nitrate for skin fungal infections, Tretinoin for photo-aging and 5-fluorouracil for psoriasis and skin cancer.
- Penetration enhancers are commonly added to dermatological treatment drugs, such as difluorenylsulfoxide (DMSO), difluorenylfluoramide, fluorenyldecylsulfoxide (US Patent No. 3,527,864), difluorenylacetamide (US Patent No. 3,472,931), and N-alkyl-2-pyrrolidone (US Patent No.
- the above-mentioned penetration enhancers have some disadvantages, for example, disulfoxide has a bad smell and body odor, causing skin burns and erythema, reducing the transparency of the crystalline skin, and even causing animal tissue necrosis (Martindale, The Extra Pharmacopoeia, pages 1461-1463, Twenty-Seventh Edition, 1977). Dimethylformamide and dimethylacetamide can also cause skin burning and erythema.
- U.S. Patent No. 5,030,451 by Trebosc et al. Discloses a cosmetic composition containing an improved caffeine derivative as an active agent, and claims that the disclosed formula has "good and long-lasting fat-decomposing properties, thus demonstrating weight loss and treatment of sebum Granular is very effective.
- Mausner U.S. Patent No. 5,215,759 provides the use of methylsilanol theophyllin acetate alginate and methylsilanol mannuronate as anti-cellulite ingredient.
- U.S. Patent No. Kligman Topical application of retinoid No. 5,051,449 can improve fat granules to a limited extent. Kligman claims to include skin thickening, increased neovascularization, and moderate to significant improvement observed with pinch test.
- Vitamin A Acid is also called Tretinoin, Retinoids. Its structure belongs to the derivative of Vitamin A. Its main function is to remove the cutin, because it can remove the uppermost layer of the cuticle of the epidermis. Keratin removal can improve pore blockage, also improve skin wrinkles, circulating blood flow around the face, reduce pigmentation marks and block skin keratinization.
- vitamin A products have side effects such as photosensitivity to the skin and excessive use resulting in dryness, redness, fever, itching, and dermatitis.
- the present invention proposes a composition for external use for transdermal administration without vitamin A acid.
- the object of the present invention is to provide a topical composition for transdermal administration.
- the composition can be used for skin maintenance and treatment to improve skin acne, acne, acne, and has no antioxidant effect of vitamin A acid. combination.
- the invention provides a composition for external use for transdermal administration, the main components of which include vitamin C 1-45% W / W, vitamin B group 1 to 5% W / W, carotene 1 to 3% W / W, Vitamin E 2-90% w / w.
- the present invention also provides a composition for external use for transdermal administration, the main components of which are vitamin C 4-15% W / W, vitamin B group 1 ⁇ 3% W / W, carotene 1 ⁇ 2% W / W, vitamins E 20-65% W / W; in the above-mentioned composition for external use, its composition also includes perfume 0.1 ⁇ 2% W / W, thickener 1 ⁇ 5% W / W, surfactant 1 ⁇ 8% W / W And the right amount of distilled water.
- the above-mentioned external composition is applied to a localized position on the skin.
- the invention also provides a topical composition for transdermal administration.
- the composition is used to prepare a medicament for treating acne, acne, and acne. It can also be used for skin care and has an antioxidant effect.
- the combination The main ingredients are vitamin C 1 ⁇ 45% W / W, vitamin B group
- the external composition provided by the present invention is mainly composed of 1 to 45% W / W vitamins (1 to 5% W / W vitamin B group, 1 to 3% W / W carotene), 2 ⁇ 90% W / W vitamin E is composed of 0.1 ⁇ 2% W / W perfume, 1 ⁇ 5% W / W thickener, 1 ⁇ 8% W / W surfactant, and the remaining distilled water. The sum of the contents of each composition is 100%.
- the external composition for transdermal administration provided by the present invention can prevent and treat skin acne, acne, and acne.
- the composition provided by the present invention can maintain the skin, can also treat and improve skin acne, acne, acne, and has an antioxidant effect. Because it does not contain vitamin A acid, it does not make the skin light sensitive. While improving the skin symptoms, it can avoid side effects such as dry skin, redness, fever, itching, and dermatitis. Even if it is used for a long time, there is no excessive problem.
- the present invention provides a topical composition for transdermal administration.
- the composition is mainly composed of vitamin C, vitamin B group, carotene, vitamin E and flavor, thickener, surfactant, and can be used topically. It is used for skin care and is a pharmaceutical composition for treating acne, acne, acne and antioxidants.
- FIG. 1 is a graph showing the difference in the amount of sebum produced after the external composition of the present invention is applied to the skin, where the abscissa is time (week), and the ordinate is the amount of sebum (g / cm 2 ).
- the invention provides a composition for external use for transdermal administration, which is a composition that does not contain vitamin A acid and can maintain skin and treat and improve skin symptoms such as acne, acne, and acne.
- the composition for external use of the present invention is mainly composed of vitamin C, vitamin B group, carotene, vitamin E, and flavor, thickener, and surfactant.
- the composition of the composition is an essential vitamin for the human body, and the main component does not contain vitamin A acid, and there is no excessive problem even if it is used for a long time. Vitamins have a small amount in the body, but their functions are extremely important. The human body cannot synthesize itself and must rely on external intake.
- vitamin C has the functions of preventing the production of lipid peroxides, promoting the formation of collagen, assisting various enzymes, delaying the aging of cells, and promoting blood circulation and reducing melanin gradually; therefore it is generally believed to help the skin Regenerates, suppresses melanin production and enhances immunity.
- Vitamin B complex is not single but several vitamins together, including vitamins
- vitamin B 2 riboflavin
- niacin vitamin B 5 (pantothenic acid), vitamin B 6 (pyridoxal), folic acid (folic acid), vitamin B 12 (cobalamin), and biotin (biotin)
- other components mainly coenzyme components, function to promote glucose oxidation, fat and protein release energy to maintain the normal function of the nervous system, necessary for cell growth, regeneration, blood cell generation and synthesis of nuclear proteins and myelin, And can activate folate auxiliary enzymes and promote red blood cell production.
- Vitamin E is considered to be an antioxidant, which can inhibit the aggregation of platelets, prevent the oxidation of red blood cell membranes to prevent them from being damaged and cause anemia, maintain the integrity of cell membranes in the tissue and promote the normal function of linoleic acid, and protect the structure and function of muscle and nerve tissue In order to increase the blood flow of the terminal blood vessels, the blood flow can be effectively improved.
- vitamin E has the above-mentioned activities, currently listed products such as vitamin E with aloe wal green (Wal Green), or products containing vitamin E L'oreal Furtur E has no record of maintaining skin or treating acne, acne, pimples, and anti-oxidants.
- composition of the present invention shows that the main component of the composition in the proportion has good efficacy. Therefore, it must be emphasized that although the composition of the present invention is composed of vitamins (3, vitamin B group, carotene, vitamin E and flavor, thickener, and surfactant), it is not inferred by conventional techniques in the technical field.
- the main ingredients of the composition of the present invention are composed of vitamin C 1 to 45% W / W, vitamin B group 1 to 5% W / W, carotene 1 to 3% W / W, vitamin E 2 to 90% W / W and fragrance 0.1. ⁇ 2% W / W, thickener 1 ⁇ 5% W / W, surfactant 1 ⁇ 8% W / W, and appropriate amount of distilled water.
- the main component ratio is preferably vitamin C 4 to 15% W / W, vitamin B group 1 to 3% W / W, carotene 1 to 2% W / W, and vitamin E 20 to 65% W / W.
- the invention provides a vitamin A-acid-free composition, which is a composition that can be administered topically to treat acne, acne, and acne. Since the present invention is composed of vitamin C, vitamin B group, carotene, vitamin E and fragrance, thickener, and surfactant, it can be applied transdermally to the skin, facial area and other extremities to achieve skin maintenance. Treatment improves acne, acne, acne and other symptoms, as well as anti-oxidation of skin.
- composition for topical administration may be added with various excipients, carriers or diluents as necessary to provide an ointment form, emulsion, lotion or patch directly applied to the affected area.
- the dosage form is added with a binder such as starch and sodium carboxymethyl cellulose in a conventional formulation method in the art, or the pH value is adjusted to a proper level by using a phosphate buffer solution; the dosage form may also be added according to a conventional formulation method.
- natural plant extracts such as licorice can also be used.
- Distilled water 15 mixes raw vitamin C, vitamin B complex, dissolved in a small amount of distilled water, and also mixes carotene, vitamin E, flavor, surfactant, and thickener. Then, mix the two solutions and make up for the amount of distilled water.
- Example 4
- Distilled water qs Mix the above raw materials Vitamin C, Vitamin B complex-dissolved in a small amount of distilled water, and mix carotene, Vitamin E, Flavor, Surfactant, Thickener Then, mix the two solutions and make up for the amount of distilled water.
- Example 6 Distilled water qs Mix the above raw materials Vitamin C, Vitamin B complex-dissolved in a small amount of distilled water, and mix carotene, Vitamin E, Flavor, Surfactant, Thickener Then, mix the two solutions and make up for the amount of distilled water.
- Thickening agent 2 Distilled water q s Dissolve the above raw materials Vitamin C, Vitamin B complex-complex in a small amount of distilled water, Carotene, Vitamin E, Flavor, Surfactant ), The thickeners are mixed, and then the two solutions are mixed and the amount of distilled water is made up.
- Vitamin E 30 Vitamin c 10 Vitamin B complex -complex 5 Carotene 2 Flavor 2 Surfactant 10 Thickening agent 5 Permeation enhancer 1.5 Distilled water qs
- the patient has a pustule with oral antibiotics, such as tetracycline or doxycycline (Vibramycin) for one week, other acne treatments, such as vitamin A acid, orally or topically, or hormone therapy .
- oral antibiotics such as tetracycline or doxycycline (Vibramycin)
- other acne treatments such as vitamin A acid, orally or topically, or hormone therapy .
- Lo-108 has the effect of treating acne, even exfoliating, reducing the amount of sebum secretion, sterilizing and anti-inflammatory, and increasing the moisture content of keratin.
- Test 2 Controlled assessment of sebum spill-out inhibition
- the test for sebum spillage is to measure the amount of oil on the skin surface using a sebometer 810 PC (Courage and Khazaka Ltd, Germany). Because of the difference in the percentage of sebum on the left and right sides, many interference variables can be minimized.
- the principle of sebum measurement is to use a 0.1 mm thick, opaque plastic material with an area of 64 mm 2 in front of the device. After pressing it on the skin surface for 30 seconds, it increases the transparency due to the absorption of sebum, and increases linearly with the amount of sebum. Sebum is directly proportional to transparency, as shown in Table 2. Measurements via a photometer can be converted to mg / cm2 via the formula. Skin fat determination
- test group and the control group are the skin on the left and right sides of the same person's forehead, interference factors such as changes in temperature and humidity, the degree of exercise of the subject, and the degree of sweating can be excluded.
- Lo-108 can effectively remove or suppress oil and fat secretion for more than 12 hours, so that the amount of open sebum in the sebaceous glands (one of the main causes of acne) can be temporarily relieved. This effect can be achieved in a short period of time, and daily use can maintain its effect of suppressing sebum for more than four weeks.
- treat * time is the interaction between treatment and time.
- Rats used in this experiment were eight weeks old, and male rats (Wistar species;) were raised at Chenggong University Animal Center, which is the only animal breeding unit in the south that meets foreign requirements (SPF). Rats were housed in an air-conditioned animal room at 25 ⁇ 1 ° C. All rats were free to eat and drink.
- This step mainly refers to the experimental method of Kistler et al., And uses the observation of animal control comparison.
- the experimental steps are as follows: each rat is anesthetized with pentobarbital at 65 mg / kg, and after it is lethargic, the back is divided into four fixed areas, each of which is about 4 cm 2 ; The inner hair is shaved clean. Then, place red iron pieces (temperature around 80-85 ° C) on the four areas of the back for about 10 seconds, causing burns to the back of the rats. After the procedure is completed, remove the iron sheet and use hydrogen peroxide (37%) for simple disinfection and clean the wound.
- This experiment uses three strains of Staphylococcus aureus,
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002525465A CA2525465A1 (en) | 2003-05-16 | 2003-05-16 | Topical composition for transdermal administration |
KR1020057021808A KR100673044B1 (ko) | 2003-05-16 | 2003-05-16 | 경피 투여용 국소 조성물 |
PCT/CN2003/000358 WO2004100923A1 (fr) | 2003-05-16 | 2003-05-16 | Composition a usage externe administree par voie percutanee |
EP03727132A EP1625844A4 (en) | 2003-05-16 | 2003-05-16 | COMPOSITION FOR EXTERNAL USE PERCUTANEOUSLY ADMINISTERED |
BRPI0318343-2A BR0318343A (pt) | 2003-05-16 | 2003-05-16 | composição tópica para administração transdérmica |
JP2004571754A JP2006525945A (ja) | 2003-05-16 | 2003-05-16 | 皮膚を通して投薬される外用組成物 |
AU2003234980A AU2003234980B2 (en) | 2003-05-16 | The composition for external use by percutaneous administration | |
US10/811,420 US7655255B2 (en) | 2003-05-16 | 2004-03-26 | Topical composition for transdermal administration |
US11/446,051 US20060222689A1 (en) | 2003-05-16 | 2006-06-02 | Skin care compositions and methods |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2003/000358 WO2004100923A1 (fr) | 2003-05-16 | 2003-05-16 | Composition a usage externe administree par voie percutanee |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004100923A1 true WO2004100923A1 (fr) | 2004-11-25 |
Family
ID=33426287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/000358 WO2004100923A1 (fr) | 2003-05-16 | 2003-05-16 | Composition a usage externe administree par voie percutanee |
Country Status (7)
Country | Link |
---|---|
US (1) | US7655255B2 (zh) |
EP (1) | EP1625844A4 (zh) |
JP (1) | JP2006525945A (zh) |
KR (1) | KR100673044B1 (zh) |
BR (1) | BR0318343A (zh) |
CA (1) | CA2525465A1 (zh) |
WO (1) | WO2004100923A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1752132A3 (en) * | 2005-08-08 | 2010-01-13 | Lotus Pharmaceutical Co., Ltd. | Skin cosmetic compositions |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7914814B2 (en) * | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
CN1250229C (zh) * | 2003-05-16 | 2006-04-12 | 美时化学制药股份有限公司 | 经皮给药的外用组合物 |
FR2866563B1 (fr) * | 2004-02-19 | 2008-01-11 | Oreal | Composition de peeling comprenant de l'acide 8-hexadecene- 1,16 dicarboxylique |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
CA2563670C (en) * | 2004-04-19 | 2014-09-16 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US7550488B2 (en) * | 2005-12-30 | 2009-06-23 | Dr. N's Health Care Products Llc | Application methods to rapidly alter disease and injury states using molecular transport of B6 |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US8604081B2 (en) | 2009-06-24 | 2013-12-10 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
EP2658551B1 (en) | 2010-12-29 | 2020-07-01 | Strategic Science & Technologies, LLC | Treatment of erectile dysfunction and other indications |
JP2014501283A (ja) | 2010-12-29 | 2014-01-20 | ストラテジック サイエンス アンド テクノロジーズ, エルエルシー | アレルギーおよび他の適応症の処置のためのシステムおよび方法 |
JP6274714B2 (ja) * | 2011-07-29 | 2018-02-07 | 株式会社ダイセル | 皮脂産生抑制剤 |
JP2014144929A (ja) * | 2013-01-29 | 2014-08-14 | Daiichi Sankyo Healthcare Co Ltd | ビタミン類を含有するニキビの予防又は治療用組成物 |
JP2015166330A (ja) * | 2014-03-04 | 2015-09-24 | 株式会社マンダム | 化粧料 |
CN108371669A (zh) * | 2018-04-18 | 2018-08-07 | 董新声 | 一种用于青春痘的外用药 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938960A (en) * | 1984-03-07 | 1990-07-03 | Roshdy Ismail | Agents for the treatment and protection of the skin |
US5710177A (en) * | 1992-12-18 | 1998-01-20 | Beiersdorf Ag | Synergistic combinations of active substance for the cosmetic or dermatological care of the skin, hair & nails |
CN1236634A (zh) * | 1998-05-22 | 1999-12-01 | 李华 | 多功能痤疮药液及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2240187A1 (de) * | 1972-08-16 | 1974-02-21 | Jereb Franz Dr Albin | Salbe |
DE3504695A1 (de) * | 1985-02-12 | 1986-08-14 | Roshdy Dipl.-Chem. Dr. 5000 Köln Ismail | Haarwuchsmittel |
LU87145A1 (fr) * | 1988-02-26 | 1989-09-20 | Oreal | Methode pour ameliorer l'aspect esthetique de la peau a l'aide de melanges polyvitaminiques |
US5602183A (en) | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
US5646190A (en) * | 1991-03-01 | 1997-07-08 | Warner-Lambert Company | Acne treating-wound healing compositions and methods for preparing and using same |
FR2681784B1 (fr) | 1991-10-01 | 1995-06-09 | Fabre Pierre Cosmetique | Composition dermatologique et/ou cosmetologique contenant des retinouides et utilisation de nouveaux retinouides. |
DE4328871A1 (de) * | 1993-08-27 | 1995-03-02 | Beiersdorf Ag | Mittel gegen empfindliche, hyperreaktive Hautzustände, atopische Dermatiden, Pruritus, Psoriasis Prurigo, Photodermatosen und Ichthyosis |
AU7787194A (en) * | 1993-09-23 | 1995-04-10 | Ali Altunkaya | Composition containing omega 3 and/or omega 6 polyunsaturated acids having from 12 to 22 carbon atoms |
JPH09291011A (ja) * | 1996-04-24 | 1997-11-11 | Kose Corp | 外用に適する組成物 |
US5804594A (en) | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
US5962517A (en) * | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
US6036946A (en) * | 1997-12-24 | 2000-03-14 | Shaklee Corporation | Methods for protecting skin from damaging effects of ultraviolet light |
CA2318345C (en) * | 1997-12-24 | 2011-06-07 | Shaklee Corporation | Composition with high efficiency skin protection from damaging effects of ultraviolet light |
US6217852B1 (en) * | 1998-08-15 | 2001-04-17 | Skinnovative Dermatologic Concepts, L.L.C. | Personal cleansing compositions having photoprotective agents |
US6630163B1 (en) * | 1999-04-22 | 2003-10-07 | Howard Murad | Method of treating dermatological disorders with fruit extracts |
-
2003
- 2003-05-16 WO PCT/CN2003/000358 patent/WO2004100923A1/zh active IP Right Grant
- 2003-05-16 KR KR1020057021808A patent/KR100673044B1/ko not_active IP Right Cessation
- 2003-05-16 EP EP03727132A patent/EP1625844A4/en not_active Withdrawn
- 2003-05-16 JP JP2004571754A patent/JP2006525945A/ja active Pending
- 2003-05-16 CA CA002525465A patent/CA2525465A1/en not_active Abandoned
- 2003-05-16 BR BRPI0318343-2A patent/BR0318343A/pt not_active IP Right Cessation
-
2004
- 2004-03-26 US US10/811,420 patent/US7655255B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938960A (en) * | 1984-03-07 | 1990-07-03 | Roshdy Ismail | Agents for the treatment and protection of the skin |
US5710177A (en) * | 1992-12-18 | 1998-01-20 | Beiersdorf Ag | Synergistic combinations of active substance for the cosmetic or dermatological care of the skin, hair & nails |
CN1236634A (zh) * | 1998-05-22 | 1999-12-01 | 李华 | 多功能痤疮药液及其制备方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1625844A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1752132A3 (en) * | 2005-08-08 | 2010-01-13 | Lotus Pharmaceutical Co., Ltd. | Skin cosmetic compositions |
Also Published As
Publication number | Publication date |
---|---|
KR100673044B1 (ko) | 2007-01-22 |
US7655255B2 (en) | 2010-02-02 |
CA2525465A1 (en) | 2004-11-25 |
JP2006525945A (ja) | 2006-11-16 |
BR0318343A (pt) | 2006-07-11 |
US20040228908A1 (en) | 2004-11-18 |
KR20060019540A (ko) | 2006-03-03 |
EP1625844A1 (en) | 2006-02-15 |
AU2003234980A1 (en) | 2004-12-03 |
EP1625844A4 (en) | 2009-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6495183B2 (ja) | 表面の創傷を処置するための組成物および方法 | |
AU2020201781B2 (en) | Composition, system and method for treating skin | |
JP4745608B2 (ja) | 電子伝達剤のリン酸誘導体を用いた皮膚治療 | |
WO2004100923A1 (fr) | Composition a usage externe administree par voie percutanee | |
US20060222689A1 (en) | Skin care compositions and methods | |
JP2011088930A (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
US11696907B2 (en) | Wound healing composition | |
JP2013163681A (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
EP1752132A2 (en) | Skin cosmetic compositions | |
JP2013177460A (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
RU2325900C2 (ru) | Состав для кожи наружного применения | |
KR20190132197A (ko) | 여드름이 생기기 쉬운 피부의 치료 및 예방에 사용하기 위한 화장품 조성물 | |
AU2006202906A1 (en) | Compositions for use with skin | |
WO2011123619A2 (en) | Permeable mixtures, methods and compositions for the skin | |
TWI325324B (zh) | ||
JP2013177461A (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
JP2013166779A (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
ZA200509183B (en) | Topical composition for transdermal administration | |
NZ721272B2 (en) | Composition, system and method for treating skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200501649 Country of ref document: VN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003727132 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12005501990 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2525465 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/09183 Country of ref document: ZA Ref document number: 200509183 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004571754 Country of ref document: JP Ref document number: 1020057021808 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2579/KOLNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005135164 Country of ref document: RU Ref document number: 2003234980 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2003727132 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057021808 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0318343 Country of ref document: BR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003234980 Country of ref document: AU |